Alyanak Ahmet, Gulen Merter, Ege Bahadır
Department of General Surgery, Yuksek Ihtisas University Affiliated Medical Park Ankara Private Hospital, Ankara, Turkey.
Department of General Surgery, Medicana Hospital, Ankara, Turkey.
Front Surg. 2022 Sep 20;9:988082. doi: 10.3389/fsurg.2022.988082. eCollection 2022.
Today's gold standard for treating chronic anal fissure is the Lateral Internal Sphincterotomy (LIS). Botulinum Toxin (BoNT) injection is, on the other hand, an alternative treatment for patients who do not want to have surgical treatment, patients undergoing chemotherapy, patients of high risk for surgery, and those who have the risk of anal incontinence (e.g., elderly, past anorectal surgery, vaginal multiple births, etc.). The aim of this study is to compare the effectiveness of BoNT and redo-LIS for treatment of post-LIS recurrent chronic anal fissure, and reveal differences if any.This study aims to compare redo-LIS and BoNT injection for treating post-LIS recurrent anal fissure.
Nineteen patients who received LIS treatment and then redo-LIS or BoNT injection due to recurrence in the follow-up were included in this study. Group I (redo-LIS group) include 11 patients and group 2 (BoNT group) includes 8 patients. Their data on age, sex, anal incontinence scores and pain (VAS score) score as well.
During the 3-month post-surgery follow-up period, there was statistically significant difference ( < 0.01) between groups by pain. No deterioration in the incontinence scores of patients in the group during the 6-month post-surgery period.
This study demonstrates that redo lateral internal sphincterotomy (LIS) is a reliable method for patients who received LIS but developed recurrent chronic anal fissure, and achieves successful results in terms of recurrence and relief of pain.
目前治疗慢性肛裂的金标准是侧方内括约肌切开术(LIS)。另一方面,肉毒杆菌毒素(BoNT)注射是一种替代治疗方法,适用于那些不愿接受手术治疗的患者、正在接受化疗的患者、手术风险高的患者以及有肛门失禁风险的患者(如老年人、既往有肛肠手术史、经阴道多次分娩等)。本研究的目的是比较BoNT和再次LIS治疗LIS术后复发性慢性肛裂的有效性,并揭示两者之间是否存在差异。本研究旨在比较再次LIS和BoNT注射治疗LIS术后复发性肛裂的效果。
本研究纳入了19例接受LIS治疗后因随访中复发而接受再次LIS或BoNT注射的患者。第一组(再次LIS组)包括11例患者,第二组(BoNT组)包括8例患者。收集了他们的年龄、性别、肛门失禁评分和疼痛(视觉模拟评分法[VAS]评分)等数据。
在术后3个月的随访期内,两组间疼痛程度存在统计学显著差异(<0.01)。术后6个月内,该组患者的失禁评分无恶化。
本研究表明,对于接受过LIS但出现复发性慢性肛裂的患者,再次侧方内括约肌切开术(LIS)是一种可靠的方法,在复发率和疼痛缓解方面均取得了成功的结果。